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Abstract
Background: Treatment of Mycobacterium ulcerans disease, or Buruli ulcer (BU), has shifted from surgery to treatment with
streptomycin(STR)+rifampin(RIF) since 2004 based on studies in a mouse model and clinical trials. We tested two entirely
oral regimens for BU treatment, rifampin(RIF)+clarithromycin(CLR) and rifapentine(RPT)+clarithromycin(CLR) in the mouse
model.
Methodology/Principal Findings: BALB/c mice were infected in the right hind footpad with M. ulcerans strain 1059 and
treated daily (5 days/week) for 4 weeks, beginning 11 days after infection. Treatment groups included an untreated control,
STR+RIF as a positive control, and test regimens of RIF, RPT, STR and CLR given alone and the RIF+CLR and RPT+CLR
combinations. The relative efficacy of the drug treatments was compared on the basis of footpad CFU counts and median
time to footpad swelling. Except for CLR, which was bacteriostatic, treatment with all other drugs reduced CFU counts by
approximately 2 or 3 log10. Median time to footpad swelling after infection was 5.5, 16, 17, 23.5 and 36.5 weeks in mice
receiving no treatment, CLR alone, RIF+CLR, RIF alone, and STR alone, respectively. At the end of follow-up, 39 weeks after
infection, only 48%, 26.4% and 16.3% of mice treated with RPT+CLR, RPT alone and STR+RIF had developed swollen
footpads. An in vitro checkerboard assay showed the interaction of CLR and RIF to be indifferent. However, in mice, co-
administration with CLR resulted in a roughly 25% decrease in the maximal serum concentration (Cmax) and area under the
serum concentration-time curve (AUC) of each rifamycin. Delaying the administration of CLR by one hour restored Cmax
and AUC values of RIF to levels obtained with RIF alone.
Conclusions/Significance: These results suggest that an entirely oral daily regimen of RPT+CLR may be at least as effective
as the currently recommended combination of injected STR+oral RIF.
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Introduction
Mycobacterium ulcerans disease, also known as Buruli ulcer (BU), is
the third most prevalent disease caused by mycobacteria [1]. It is
characterized by deep and necrotizing skin ulcers with under-
mined edges resulting from the secretion by M. ulcerans of an
immunosuppressive macrolide toxin, termed mycolactone [2]. It is
predominantly found in scattered foci in tropical riverine and
marshy regions throughout the world. In certain parts of Africa its
prevalence may exceed 150/100,000 individuals [3].
Until 2004, the recommended treatment for BU was surgical
excision and skin grafting [1]. However, experimental studies
using the mouse footpad model demonstrated that the combina-
tion of rifampin (RIF) and an aminoglycoside was bactericidal for
M. ulcerans [4,5,6,7]. Based on these findings and subsequent
studies in humans [8,9] the daily administration of the
streptomycin-rifampin (STR+RIF) combination for 2 months
was recommended by the World Health Organization (WHO)
for the treatment of BU [10]. Depending on the size, severity and
location of the ulcer, additional surgical intervention with skin
grafting was also recommended. Treatment with STR requires
intramuscular injection, which is difficult and expensive to
implement in resource-poor countries since it requires use of
sterile needles and syringes to avoid infection with blood borne
pathogens. Therefore, the development of an entirely oral regimen
is desirable [11].
In vitro, M. ulcerans is susceptible to a limited number of oral
antibiotics including fluoroquinolones and macrolides [12,13,14,
15,16]. However, in the mouse model, the combination of
clarithromycin (CLR), a bacteriostatic or weakly bactericidal drug
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activity [4,6] has not consistently shown efficacy similar to the
standard STR+RIF regimen. Three mouse studies assessing the
bactericidal activity and the relapse rate after treatment comple-
tion yielded conflicting results. In the first study [5], the oral
combination was less effective than the standard aminoglycoside
plus RIF combination whereas in the second and third [12,13]
studies, both combinations appeared to be as effective as the
STR+RIF controls. There is, therefore, a need to directly address
the issue of oral antibiotic treatment of BU, both with RIF and
CLR and with new treatment regimens including anti-BU drugs
that may have improved activity. Rifapentine (RPT), a rifamycin
derivative with a much longer half-life than RIF could be an ideal
substitute. In the murine model of tuberculosis when substituted
for RIF at 10 mg/kg in a daily regimen in combination with
isoniazid and pyrazinamide, it shortened the duration of treatment
necessary to achieve cure [17,18]. Such regimens are currently
under evaluation in at least 3 Phase II trials for tuberculosis
treatment. In a murine model of M. ulcerans disease, daily RPT at
the lower dose of 5 mg/kg has also been shown to be as active as,
or even more active than, daily RIF at 10 mg/kg [13].
In this study, we hypothesized that the use of daily RPT along
with CLR would increase the efficacy of the rifamycin-CLR
combination and help in the development of an entirely oral
regimen for treatment of BU. We first demonstrated that there were
no negative in vitro interactions of CLR and RIF (as a representative
rifamycin) and then compared the efficacy of the RIF+CLR
regimen to that of the RPT+CLR regimen using the STR+RIF
standard regimen as control to determine whether daily RPT is a
better substitute for daily RIF in the treatment of M. ulcerans
disease in this murine model and whether daily RPT+CLR is also a
better substitute for the standard daily STR+RIF combination.
Materials and Methods
Antimicrobials
STR and RIF were purchased from Sigma (St. Louis, MO) and
RPT was a gift from sanofi-aventis pharmaceuticals (Paris,
France). CLR was a gift from Abbott Laboratories (Abbott Park,
U.S.A.). Stock solutions of RIF, RPT and CLR were prepared in
sterile 0.05% agarose solution and STR was prepared in sterile
normal saline. All stock solutions were prepared weekly and were
stored at 4uC. All antimicrobials were administered orally (by
gavage) using an esophageal cannula, except STR which was given
by subcutaneous injections.
Bacterial strain
A recent isolate of M. ulcerans from a Ghanaian patient, strain
Mu1059 [19] provided by Dr. Pamela Small, was used for the
study.
In vitro checkerboard study
To determine whether the RIF and CLR interaction is
synergistic, indifferent or antagonistic, serial two-fold concentra-
tions ranging from 0.125 to 2 mg/ml of both drugs alone and in
combination were prepared in 7H11 agar+Oleic Acid-Albumin-
Dextrose-Catalase (OADC) supplement. Eight-week-old colonies
of Mu1059 from 7H11 agar plates were suspended in phosphate-
buffered saline (PBS), briefly vortexed, and kept undisturbed for
30 minutes to allow larger particles to settle. The optical density at
600 nm of this suspension was adjusted to 1, and 500 ml of the
appropriate dilutions were plated in duplicate on antibiotic-
containing plates and control plates without antibiotic. Plates were
incubated at 32uC, and final CFU counts were performed after 12
weeks. The MIC was defined as the lowest drug concentration to
inhibit growth of at least 99% of CFU on drug-free control plates.
The fractional inhibitory concentration (FIC) value of individual
drugs was then calculated using the MIC of the drug alone and
MIC of the drug in combination. The sums of the two FIC values
were combined to give the SFIC value which was then used to
determine whether synergism (SFIC#0.5), indifference SFIC
(.0.5 to #4) or antagonism (SFIC.4) occurred between the
antibacterial agents. All calculations were performed in accor-
dance with current accepted standards [20,21,22].
Inoculum preparation for the in vivo study
For each infection, an aliquot of a twice-mouse-passaged
Mu1059 strain stored at 280uC was thawed and inoculated in
mouse footpads. Once the footpads were swollen to a lesion index
of 2–3 (defined as inflammatory footpad/hind foot swelling) [5],
mice were sacrificed and footpad tissue was harvested, minced and
suspended in sterile PBS. The solution was vortexed briefly,
allowed to stand for 30 minutes, and the supernatant was used for
footpad infection. Prior to infection, the inoculum was checked
qualitatively for acid-fast bacilli, serially diluted, and plated for
CFU counts on Middlebrook selective 7H11 plates (Becton-
Dickinson, Sparks, MD).
Mouse model, infection and treatment
The kinetic method developed by Shepard for assessing the
activity of anti-leprosy drugs [4,5,6,23,24] was used to assess drug
activity. In brief, 320 female BALB/c mice aged 4-to-6 weeks
(Charles River, Wilmington, MA) were infected in the right hind
footpad with 0.03 ml of the M. ulcerans suspension. After infection,
mice were randomized to one of two control groups or one of six
test groups. The control groups included untreated negative
controls (n=50), and mice treated with STR+RIF as positive
controls (n=55). The test groups included mice treated with each
antibiotic alone, i.e., CLR (n=30), STR (n=25), RIF (n=25),
and RPT (n=25), and the two-drug combinations RIF+CLR
(n=55) and RPT+CLR (n=55). Ten mice from the untreated
Author Summary
Buruli ulcer (BU) is found throughout the world but is
particularly prevalent in West Africa. Until 2004, treatment
for this disfiguring disease was surgical excision followed
by skin grafting, procedures often requiring months of
hospitalization. More recently, an 8-week regimen of oral
rifampin and streptomycin administered by injection has
become the standard of care recommended by the World
Health Organization. However, daily injections require
sterile needles and syringes to prevent spread of blood
borne pathogens and streptomycin has potentially serious
side effects, most notably hearing loss. We tested an
entirely oral regimen, substituting the long acting
rifapentine for rifampin and clarithromycin for streptomy-
cin. We also evaluated each drug separately. We found
that rifapentine alone is as good as rifampin plus
streptomycin, but the simultaneous addition of effective
clarithromycin doses, at least in the mouse, reduces the
activity of both rifampin and rifapentine, making it difficult
to assess the efficacy of the oral regimens in the model.
Studies of serum drug concentrations indicated that
separating treatment times by one hour or reducing the
clarithromycin dose to one active in humans should
overcome this issue in experimental and clinical BU
treatment, respectively.
Oral Therapy for Buruli Ulcer in Mice
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at treatment initiation (D11) to establish baseline CFU counts in
the footpads. All mice were treated for 4 weeks, 5 days per week.
The drugs were given at the following doses that are equivalent
(similar AUC) to the human doses [25,26]: RIF 10 mg/kg, RPT
10 mg/kg, STR 150 mg/kg and CLR 100 mg/kg. On treatment
completion, 5 mice from each group were sacrificed for
quantitative CFU counts in the footpads and all of the remaining
mice were kept without treatment to determine the time to footpad
swelling.
For quantitative footpad CFU counts, each footpad was
harvested after having been thoroughly disinfected with soap
and sterile PBS followed by 70% alcohol swabs. The footpad tissue
was homogenized by fine mincing and suspended in 2 ml sterile
PBS. Appropriate dilutions were plated on selective 7H11 plates
and incubated at 32uC for 12 weeks before CFU were
enumerated. This study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal procedures were approved by the Johns Hopkins Animal
Care and Use Committee (protocol MO08M240) and conducted
according to relevant national and international guidelines.
Assessment of treatment efficacy
The activity of each treatment was assessed in terms of CFU
counts on treatment completion and median time to footpad
swelling in treated mice compared with untreated control mice.
CFU counts were performed by harvesting and homogenizing the
footpad as described above and suspending each footpad in 2 ml
PBS. Serial 10-fold dilutions were prepared and 0.5 ml of
appropriate dilutions were plated in duplicate on 7H11 selective
plates. The plates were then incubated at 32uC for 12 weeks before
the CFU counts were made. Median time to footpad swelling was
assessed by checking the footpads of mice every week for 39 weeks
after infection. If the median time to footpad swelling in treated
mice exceeded that in untreated mice by no more than the
duration of the treatment, i.e. 4 weeks, then the treatment was
considered to be bacteriostatic. Longer median time to swelling
was indicative of bactericidal activity or prolonged post-antibiotic
effect. Absence of swelling at the end of the follow-up period was
indicative of sterilizing potential.
Pharmacokinetic studies of rifamycin-CLR combinations
Because we observed a negative antimicrobial interaction
between both rifamycin derivatives and CLR in vivo, a series of
single-dose pharmacokinetic (PK) studies were performed in
BALB/c mice. In the first study mice were co-administered
100 mg/kg of CLR and RIF 10 mg/kg. One sample for PK
analysis was collected per mouse at 1, 2, 4, 6, 9 or 16 hrs after
dosing. From these data, composite concentration-time curves
were developed and compared. Because RIF serum concentrations
appeared to be diminished when the two drugs were dosed
together, we conducted a second study in which mice received
10 mg/kg of RIF alone, 10 mg/kg of RIF followed by 100 mg/kg
of CLR one hour later, or 10 mg/kg of RIF co-administered with
a lower dose of CLR (10 mg/kg). In a third study we substituted
RPT for RIF and assessed RPT serum concentrations in mice
receiving 10 mg/kg of RPT alone, 10 mg/kg of RPT co-
administered with 100 mg/kg of CLR, or 10 mg/kg of RPT
followed 1 hour later by 100 mg/kg of CLR. In a fourth study we
evaluated RPT serum concentrations after RPT 10 mg/kg was co-
administered with CLR at 10 mg/kg. Serum samples were frozen
at 280uC and shipped overnight on dry ice to the Infectious
Disease Pharmacokinetics Laboratory, National Jewish Medical
and Research Center, Denver, CO. Drug concentrations were
determined using validated HPLC methods. PK parameters were
calculated using non compartmental methods with Phoenix
WinNonlin software, version 6.1.0 (Pharsight, Cary, NC).
Statistical analysis
Survival analysis, with footpad swelling as the measurement,
was performed using the Kaplan-Meier method [27]. The log rank
test was used to determine the level of statistical significance when
comparing survival curves of the different treatment groups with
the control group. p values were two-tailed, and a value of p,0.05
was considered statistically significant. CFU counts were log-
transformed before analysis. Culture-negative footpads were
assigned a log value of 0. Group means for experimental treatment
groups were compared with that of the standard treatment control
by one-way analysis of variance with Dunnett’s post-test. Paired t-
tests were also used to compare groups of equal size. All analyses
were performed with GraphPad Prism version 4.01 (GraphPad,
San Diego, CA).
Results
Checkerboard assay
The results of the checkerboard study are shown in table 1.
They indicated that the interaction (SFIC=0.75) between the two
drugs was neither synergistic nor antagonistic and therefore was
termed indifferent using the current guidelines [20,21,22].
CFU counts
The initial footpad suspension used for the inoculum contained
5.76 log10 CFU per ml or 4.24 log10 in the 0.03 ml that was
inoculated per footpad. The next day (D1) 10 mice were sacrificed
and the mean CFU count per footpad was 3.2960.41 log10.O n
initiation of treatment, 11 days after infection (D11), the mean
CFU count in the 10 mice that were sacrificed was 3.3560.16
log10 CFU, indicating that there was no substantial multiplication
in the footpads during the first 11 days.
On treatment completion (Figure 1), 4 weeks later, the mean
log10 CFU count was 5.0160.62 in untreated control mice (W4
UT), demonstrating that M.ulcerans had multiplied well, increasing
by about 2 log10 in the footpads during the 4 weeks following
treatment initiation, and suggesting a division time close to 4 days.
In the positive control mice treated with STR+RIF, the mean
log10 CFU count was 0.7660.52, with one footpad out of the 5
harvested footpads culture-negative, underscoring the potent
bactericidal activity of the STR+RIF combination against actively
multiplying M. ulcerans. Among the test mice, the mean log10 CFU
count was 3.5460.18 in mice treated with CLR alone, a value
similar to the 3.3560.16 log10 value on treatment initiation,
confirming the bacteriostatic activity of CLR against actively
multiplying M. ulcerans. For other antibiotics alone or in
Table 1. Checkerboard analysis for in-vitro interaction
between clarithromycin (CLR) and rifampin (RIF).
Alone In-combination FIC SFIC
MIC of CLR 0.5 0.125 0.25 0.75
MIC of RIF 0.25 0.125 0.5
FIC=MIC of the drug in combination4MIC of the drug alone.
SFIC=FIC of CLR+FIC of RIF.
doi:10.1371/journal.pntd.0000933.t001
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log10 CFU counts were significantly reduced (p,0.01) compared
to the baseline value (Figure 1) but were not significantly different
from each other except that mice treated with STR+RIF had a
lower mean CFU count compared to RIF alone by paired t-test
analysis (p=0.0335, though not significant after adjustment for
multiple comparisons): 0.8260.58 for STR alone (no CFU was
isolated from 1 of the 5 mice); 1.3360.24 for RIF alone and
1.3761.15 for RIF+CLR (no CFU was isolated from 1 of the 5
mice); 0.4860.56 for RPT alone (no CFU was isolated from 2 of
the 5 mice) and 0.2060.31 for RPT+CLR (no CFU was isolated
from 3 of the 5 mice).
Time to footpad swelling
After completing 4 weeks of treatment, mice were monitored on
a weekly basis for footpad swelling. Time to median swelling in
untreated mice was 5 weeks after infection (Figure 2). In
accordance with the CFU counts on treatment completion, mice
treated with CLR were the first to reach footpad swelling. But the
median time to swelling was 16 weeks after infection, well beyond
the 9 weeks that would have been expected after 4 weeks of
treatment with a purely bacteriostatic drug added to the 5 weeks
time to swelling in untreated control mice. CLR treatment is thus
accompanied by a prolonged delay in footpad swelling possibly
due to a significant post-antibiotic effect. Mice treated by CLR
were followed by mice treated by RIF alone and STR alone, with
median time to footpad swelling of 23.5 and 34 weeks,
respectively. Only 26.3% of mice treated with RPT alone and
11.4% of the positive controls treated with STR+RIF developed
footpad swelling at the end of the 8-month follow-up period after
treatment completion, emphasizing the potent sterilizing effect of
both regimens. The difference between RPT alone and STR+RIF
was not statistically significant (p=0.33).
Surprisingly, as illustrated in Figure 2B, the time to footpad
swelling was much shorter in mice treated with RIF+CLR
(p,0.008) or RPT+CLR (p=0.116) than in mice treated with
RIF alone or RPT alone, respectively, suggesting antimicrobial or
pharmacological antagonism between rifamycins and CLR in the
mouse. Despite this antagonism, however, the RPT+CLR regimen
caused a significantly greater (p=0.0007) delay in footpad swelling
than did RIF+CLR. Because the checkerboard study did not
reveal antagonism between the two antimicrobials, the antagonism
was likely to be due to pharmacokinetic drug-drug interaction as
demonstrated below.
Impact of CLR administration on rifamycin
pharmacokinetics
In the first PK study, as in the second and third PK studies, the
experiments were performed as single and first-dose assessments,
RIF (10 mg/kg) was either administered alone or co-administered
with CLR (100 mg/kg). The mean AUC0–16h and Cmax of RIF
were 118.63618 mg*hr/ml and 11.9761.3 mg/ml, respectively,
when RIF was administered alone, and 92.5627 mg*hr/ml and
8.4860.54 mg/ml, respectively, when RIF was co-administered
with CLR (Figure 3A), suggesting that CLR co-administration led
to diminished RIF concentrations. In a second PK study, RIF
(10 mg/kg) was administered alone, with CLR (100 mg/kg) given
1 hr later, or co-administered together with CLR at a lower dose
of 10 mg/kg. The mean AUC0–21h and Cmax of RIF were
123621 mg*hr/ml and 15.764.2 mg/ml, respectively, when RIF
was administered alone, 133632 mg*hr/ml and 16.762.5 mg/ml,
respectively, when CLR (100 mg/kg) was administered 1 hr after
RIF, and 125622 mg*hr/ml and 15.561.2 mg/ml, respectively
when RIF and CLR were co-administered at an equal dose of
10 mg/kg (Figure 3B).
Similar observations were made in mice given RPT and CLR.
The AUC0–24h and Cmax of RPT were moderately decreased
from 317.24625 mg*hr/ml and 18.1161.0 mg/ml, respectively,
when RPT was given alone to 241.0960.37 mg*hr/ml and
13.0761.6mg/ml, respectively, when RPT was co-administered
with CLR (100 mg/kg). Delaying administration of CLR (100mg/
kg) by 1 hr resulted in a RPT AUC0–24hof 279.7060.47 mg*hr/ml
and Cmax of 15.1461.7 mg/ml (figure 4A). Reducing the dose of
CLR to 10 mg/kg when co-administered with 10 mg/kg RPT
resulted in RPT AUC0–24hand Cmax values of 302.51628 mg*hr/
ml and 17.5261.1 mg/ml, respectively, similar to those of
324.23644 mg*hr/ml and 19.2461.6 mg/ml, respectively, ob-
tained with RPT alone (Figure 4B).
Discussion
The main result of the present work is that RPT alone
administered 5 days a week at a dose of 10mg/kg is at least as
active in terms of bactericidal effect and as active in terms of
relapse prevention as the standard combination of STR+RIF
against experimental M.ulcerans disease in the mouse. Such a result
is extremely promising for the future of M.ulcerans disease
treatment because it suggests that an entirely oral treatment may
be as active as the present regimen containing parenteral STR.
However, RPT cannot be administered alone because of the risk
of drug resistance resulting from monotherapy, and CLR is the
oral companion drug of choice to combine with a rifamycin [28].
As CLR alone exhibited clear-cut bacteriostatic activity, an
additive effect of the combination RPT+CLR and even RIF+CLR
was expected. Unfortunately the co-administration of a rifamycin
and CLR, both drugs given orally at doses equivalent to human
doses on the basis of serum AUC, was less effective than each
rifamycin alone in mice infected with M. ulcerans.A sn o
antagonistic effect between RIF and CLR was exhibited in vitro
in the checkerboard assay, the lesser in vivo effectiveness of the
combination could not be related to a negative antimicrobial drug-
drug interaction. Rather, it appears that the negative drug-drug
interaction was pharmacokinetic in nature. Indeed, co-adminis-
tration of a 10-mg/kg dose of RIF with a 100 mg/kg dose of CLR
resulted in a 22% reduction of RIF AUC and a 29% reduction of
RIF Cmax compared to administration of RIF alone. Similarly,
Figure 1. Reduction in footpad CFU counts with various
treatment regimens. Mean CFU count from mouse footpads on the
day after infection (Day1), the day of treatment initiation (D11), and
after four weeks of: UT=no treatment, CLR=clarithromycin, RIF=ri-
fampin, STR=streptomycin, RPT=rifapentine, The number of asterisks
below the x-axis indicates the number of mice with negative footpad
cultures.
doi:10.1371/journal.pntd.0000933.g001
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24% and 28% reduction of the RPT AUC and Cmax,
respectively, compared to RPT administered alone. When
administration of 100mg/kg of CLR was delayed by one hour
from RIF administration, the pharmacokinetic interaction became
insignificant. Similarly, there were also no negative pharmacoki-
netic drug-drug interactions when mice were co-administered
10 mg/kg of RIF and 10 mg/kg of CLR. These results indicate
that the co-administration of CLR and RIF negatively interacts
with the blood levels of rifamycins in mice probably by interfering
with their absorption or by another mechanism and that this drug
interaction is dose-dependent. However, a recent study in humans
showed that concomitant CLR did not impact the absorption rate
constant, the Cmax, or the Tmax of RIF at steady state, indicating
that, at clinically relevant doses (7.5 mg/kg of CLR and 10 mg/kg
of RIF), CLR does not negatively affect the levels of rifamycins in
humans [29].
Our findings illustrate the difficulties in designing experiments
in the murine model that aim to instruct treatment of a human
infectious disease and in interpreting their results.
In order to adequately assess in mice the antimicrobial potential
of a given drug, that drug should be given at doses deemed
equivalent to human doses. As, drugs are usually metabolized
much more rapidly in mice than in humans, the drug doses in
mice have to be increased to obtain similar drug exposure in mice
as in humans [25,30]. That is the case for CLR [30,31]. But the
dose of 100 mg/kg that is adequate in mice to assess the
antimicrobial activity of CLR when the drug is used alone
presents a problem when it is co-administered with 10 mg/kg of
RIF, most likely by reducing the absorption of RIF. Therefore the
fact that combinations of CLR and a rifamycin were less active
than the corresponding rifamycin alone should be considered an
experimental artifact, and both drugs should be administered
separately, with an interval of no less than one hour between them.
Figure 2. Delay in footpad swelling in mice receiving different drug regimens. Kaplan-Meier curve depicting the percentage of mice free of
footpad swelling during 39 weeks of follow-up after infection. The dotted vertical line shows the expected delay in time to swelling for a
bacteriostatic drug. The dotted horizontal line indicates footpad swelling in 50% of mice. A) Single drug regimens: Effect of single drugs compared to
the standard regimen STR+RIF. Rifapentine alone prevented relapse as well as the standard STR+RIF regimen and better than any other single drug. B)
Combination drug regimens with a rifamycin6CLR: Effect of adding CLR to either RIF or RPT. CLR=clarithromycin; RIF=rifampin; RPT=rifapentine,
STR=streptomycin.
doi:10.1371/journal.pntd.0000933.g002
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mental chemotherapy of tuberculosis for which RIF should be
administered at least one hour before isoniazid and pyrazinamide
to prevent a negative pharmacokinetic interaction in mice [32,33].
Although the negative pharmacokinetic interactions prevented a
reliable assessment of the antimicrobial activity of the RIF+CLR
and RPT+CLR combinations against experimental M.ulcerans
disease in mice, they did not prevent assessment of each drug alone
in reference to the positive controls receiving STR+RIF. Besides
the promising potency of RPT, our study also emphasizes the
peculiar prolonged delay in footpad swelling resulting from
treatment with CLR in mice infected with M. ulcerans. Whatever
its antimicrobial or immunomodulatory [34] nature, this delay in
footpad swelling is favorable and supports the use of CLR in the
treatment of Buruli ulcer.
Finally, it is important to note that, in our experimental model,
drug activity was assessed during a 4-week period during which
untreated animals had a 2 log10 increase in CFU counts in their
footpads. As expected, CLR exhibited bacteriostatic activity
whereas other drugs exhibited bactericidal activity, especially
RPT. But, very interestingly, even the most active drugs and drug
regimens did not reduce the CFU counts by more than 3 log10 in 4
weeks. This was much less than the 5–6 log10 reduction in the
CFU counts observed by Ji et al. [12,13,14] when treatment was
initiated at the plateau phase of growth, i.e., when the organisms
were no longer actively multiplying likely because of immune
Figure 3. Effects of CLR administration on RIF concentrations. The reduction of serum RIF concentration by co-administered CLR is overcome
by delayed CLR administration. RIF serum concentrations in mice after, A) RIF (10 mg/kg) given alone and co-administered with clarithromycin (CLR)
(100 mg/kg), and; B) RIF given alone, with CLR (100 mg/kg) administered 1 hr later, or concurrently with CLR (10 mg/kg).
doi:10.1371/journal.pntd.0000933.g003
Figure 4. Effect of CLR administration on RPT concentrations. The reduction of serum RPT concentrations by co-administered CLA is
overcome by delayed CLR administration. RPT serum concentrations in mice after, A) RPT (10mg/kg) given alone; RPT (10 mg/kg) followed by
clarithromycin (CLR) (100 mg/kg) administered 1 hr later; or RPT (10 mg/kg) and CLR (100 mg/kg) concurrently; and B) RPT (10 mg/kg) given alone
versus co-administered with lower-dose CLR (10 mg/kg).
doi:10.1371/journal.pntd.0000933.g004
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www.plosntds.org 6 January 2011 | Volume 5 | Issue 1 | e933containment. In our experimental model because antibiotic
treatment was initiated during the incubation phase of the disease,
the reduction in the CFU counts and the time to foot pad swelling
are measuring only the antimicrobial activity. When treatment is
initiated at the plateau phase of growth, its effect is likely a mixture
of antimicrobial activity, immune containment, and shutting down
the enzymes involved in mycolactone production. It does not
facilitate the assessment of the respective antimicrobial value of
each drug regimen, even though it might better recapitulate the
response of patients to antibiotic therapy. In the chemotherapy of
BU, as in the chemotherapy of tuberculosis, the drug activity
against actively multiplying organisms, usually termed bactericidal
activity, is very different from the drug activity against organisms
that are no longer actively multiplying, i.e., sterilizing activity.
Consequently, the occurrence, magnitude, and duration of the
antimicrobial effect depend on the experimental model used. The
information provided by each model is therefore different yet
complementary, and not at all contradictory.
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